Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ambroxol Lozenge vs Syrup
NCT02194296Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 1999
- Primary completion
- Jul 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of ambroxol in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration of the analyte in plasma at 36 hours and Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity at 36 hours. Started Jun 1999; status: completed.
02
Drugs
ambroxol
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT02194296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194296.